a b s t r a c t 22 Cytochromes P450 (CYPs or P450s) contain a highly conserved threonine residue in the active site, which 23 is referred to as Thr302 in the amino acid sequence of CYP2B4. Extensive biochemical and crystallo- 24 graphic studies have established that this Thr302 plays a critical role in activating molecular oxygen to 25 generate Compound I, a putative iron(IV)-oxo porphyrin cation radical, that carries out the preliminary 26 oxygenation of CYP substrates. Because of its proximity to the center of the P450 active site, this 27 Thr302 is susceptible to mechanism-based inactivation under certain conditions. In this article, we 28 review recent studies on the mechanism-based inactivation of three mammalian P450s in the 2B family, 29 CYP2B1 (rat), 2B4 (rabbit) and 2B6 (human) by tert-butylphenylacetylene (tBPA). These studies showed 30 that tBPA is a potent mechanism-based inactivator of CYP2B1, 2B4 and 2B6 with high k inact /K I ratios 31 (0.23-2.3 min À1 lM
À1
) and low partition ratios (0-5). Furthermore, mechanistic studies revealed that 32 tBPA inactivates these three CYP2B enzymes through the formation of a single ester adduct with the 33 Thr302 in the active site. These inhibitory properties of tBPA allowed the preparation of a modified 34 CYP2B4 where the Thr302 was covalently and stoichiometrically labeled by a reactive intermediate of 35 tBPA in quantities large enough to permit spectroscopic and crystallographic studies of the consequences 36 of covalent modification of Thr302. Molecular modeling studies revealed a unique binding mode of tBPA 37 in the active site that may shed light on the potency of this inhibition. The results from these studies may 38 serve as a basis for designing more specific and potent inhibitors for P450s by targeting this highly con-39 served threonine residue which is present in the active sites of most mammalian P450s. 40 
Introduction

44
The cytochromes P450 (CYPs or P450s) are members of a super- 45 family of hemoproteins that catalyze the oxidation of a vast num- 46 ber of organic compounds including many endogenous compounds 47 such as fatty acids, steroid hormones, and eicosanoids, and numer- 48 ous xenobiotic compounds including drugs, chemical carcinogens 49 and environmental pollutants. The P450s are one of the most ver- 50 satile enzymes in nature. The general reaction for P450-catalyzed 51 reactions is expressed as: arylamines, cyclic tertiary amines and furanocoumarins [4, 5] . acceptor [22] . [22] . The distances between the heteroatoms are taken from the crystal structure of the P450cam WT dioxygen complex. This figure is reproduced from Fig. 4 of Ref. [22] . Table 1 Summary of kinetic inactivation constants for acetylenic mechanism-based inhibitors of P450s. a Abbreviations: 2EN, 2-ethynylnaphthalene; 9-EPh, 9-ethynylphenanthrene; 5-P1P, 5-phenyl-1-pentyne; 17EE, 17a-ethynylestradiol; tBA, tert-butyl acetylene; tBMP, tert-butyl-1-methyl-2-propynyl ether; tBPA, tert-butylphenylacetylene; 4-P1B, 4-phenyl-1-butyne; 2-P3B2, 2-phenyl-3-buty-2-ol; 1-P2P1, 1-phenyl-2-propyn-1-ol; DMPB, CYP2B4 and CYP2B6 [45, 46] . As shown in Fig. 3 strates. With three substrates tested, i.e. 7-ethoxy-4-trifluorom-545 ethylcoumarin (7-EFC), benzphetamine and testosterone, the Many acetylenic compounds are known to be mechanism-based 555 inhibitors of P450s (see Table 1 
613
The crystal structure of the K262R variant of CYP2B6 was re-614 cently resolved and it showed that the overall structure of CYP2B6 615 is very similar to that of CYP2B4 [52] . Based on this crystal struc-616 ture, the mutation of K262 ? R occurs on the periphery of CYP2B6.
617
Thus we would suggest that its active-site architecture is represen-618 tative of that of the wild type CYP2B6 enzyme and that this crystal 
